StockData
Repligen Corp logo

Repligen Corp (RGEN) stock

RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30132% above fair value
$162.18−0.60 (-0.37%)

Close on Nov 17, 2026Market cap $10.37BP/E –Yield –

Repligen price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Repligen's price to sales ratio was 12.4× on Nov 11, 2026, against 13.6× a year earlier. Over the last 5 years it ranged from 9.0× to 24.7×, with a median of 12.7×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202612.4×−0.6
2025Dec 31, 202513.0×+0.3
2024Dec 31, 202412.7×−2.6
2023Dec 29, 202315.4×+3.6
2022Dec 30, 202211.7×−13.0
2021Dec 31, 202124.7×−6.1
2020Dec 31, 202030.8×+11.8
2019Dec 31, 201919.1×+6.5
2018Dec 31, 201812.6×−0.0
2017Dec 29, 201712.6×+2.2
2016Dec 30, 201610.4×−1.5
2015Dec 31, 201511.9×+1.5
2014Dec 31, 201410.4×−5.6
2013Dec 31, 201315.9×+8.8
2012Dec 31, 20127.1×+3.2
2011Dec 30, 20113.9×−3.0
2010Dec 31, 20106.9×–

More Repligen figures

See a number that looks wrong?